Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that its Board of Directors has approved a one-for-twelve (1-for-12) reverse stock split of its common stock that will become effective Friday, April 12, 2019, upon the filing of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of the State of Delaware. Beginning on April 12, 2019, Rexahn’s common stock will trade on NYSE American on a reverse split-adjusted basis under the new CUSIP number 761640309.
{iframe}https://investors.rexahn.com/press-releases/detail/298/rexahn-announces-reverse-stock-split{/iframe}